CoV AVC / Cidara Therap - LARVOL DELTA

[VIRTUAL] Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models (IDWeek 2020) - " CD377 and comparators (oseltamivir [OS], zanamivir [ZA], baloxavir marboxil [BM]) were evaluated in vitro by neuraminidase inhibition (NAI), and cytopathic effect (CPE) assays. CD377 exhibited potent in vitro activity and had similar PK in IC and ID mice. In efficacy studies, CD377 demonstrated robust potency in both IC and ID mouse models at equivalent doses (0.1 mg/kg, SC, single dose). These results support further development of CD377 as a novel antiviral for the prevention and treatment of influenza infection, including in people with immune deficiencies and higher risk of infection.Balb/c and Balb/c SCID"

Preclinical • Infectious Disease

[VIRTUAL] CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models (IDWeek 2020) - "Background: AVCs (antiviral Fc-conjugates) are novel, long-acting immunotherapeutic conjugates of potent antivirals conjugated to the Fc domain of human IgG1. CD377 demonstrated superior viral load reduction compared to oseltamivir in lethal influenza A (H1N1) mouse and ferret models. These data support further development of CD377 for prevention and treatment of influenza infection."

Preclinical • Infectious Disease

[VIRTUAL] New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single (IDWeek 2020) - "Background: CD377 is a novel antiviral Fc-conjugate (AVC) development candidate for influenza prevention and treatment, comprising multiple copies of a novel potent small-molecule antiviral and the Fc domain of human IgG1... The stability and safety of CD377, together with its long half-life and efficacy with a single dose, support the potential of CD377 as a long-acting, novel AVC for the prevention and treatment of influenza."

Infectious Disease

[VIRTUAL] efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models (IDWeek 2020) - "A single dose of CD377 (0.3 mg/kg or less) was protective against lethal challenge with several seasonal influenza A/B subtypes. The exceptional PK profile of CD377 combined with potent broad-spectrum activity highlight its potential for use as a long-term preventative against seasonal influenza.Seasonal influenza efficacy"

Preclinical • Infectious Disease

[VIRTUAL] Fc-mediated Fcγ receptor engagement of CD377, a novel antiviral Fc-conjugate, translates into potent antibody- dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity activity (ECCMID 2020) - "CD377 triggers potent, broad-spectrum induction of ADCP and ADCC, thereby contributing to immune defense against multiple seasonal and pandemic influenza A and B strains. This potent induction of Fc-mediated effector function of CD377 in combination with potent efficacy in lethal mouse models of influenza infection support further development of CD377 for the prevention and treatment of influenza infection."

Infectious Disease